Drugs / GVAX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00258687 | Jan 2005 → Jul 2006 | alveolar soft part sarcoma, clear cell sarcoma, melanoma, renal cell carcinoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GVAX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00258687 ↗ |
| Modality | Vaccine | “developing a vaccine” NCT00258687 ↗ |
| Route | Intramuscular | “go under the skin or into muscle” NCT00258687 ↗ |
| Route | Subcutaneous | “go under the skin or into muscle” NCT00258687 ↗ |